Stanford researchers have developed one of the smallest, active translational enhancers that can be adapted to control gene regulation. The translation enhancer is a short RNA stem-loop structure isolated from a Hox gene.
Stanford researchers have discovered that ribonucleoside vanadyl complexes can be used as an additive in transcription reactions resulting in ~2-fold increased yield.
Researchers at Stanford have developed, for the first time, a high-throughput method to systematically detect and identify silencer elements in the human genome.
Heart rhythm disorders are difficult to treat with conventional drug therapy and intraoperative injury to the cardiac conduction system (CCS) complicates heart-related surgeries and is a major cause of morbidity and mortality.
Stanford researchers at the Bao Research Group have developed a second-generation stretchable multi-sensor tag technology for detecting physiological signals.
Stanford researchers in the Richard Zare Lab have developed dual-function nanoparticles that selectively accumulate in immune-suppressing myeloid cells in tumors, allowing these cells to be both imaged and treated with a single agent.
Using a novel convolutional neural network architecture, PlexusNet can be used for histologic image analysis with smaller parameter and training sets than current state-of-the-art models.
Stanford researchers have formulated a risk scoring calculator using a human induced pluripotent stem cell (iPSC) model to accurately predict and calculate insulin resistance via a novel blood test.
Stanford researchers at the Liao and Xing Labs have developed and tested a machine learning algorithm for augmented detection of bladder cancer. Machine learning has the potential to enhance medical decision making in cancer detection and image analysis.
Coronary artery bypass grafting (CABG) surgery is performed on nearly half a million patients with multivessel or diffuse coronary artery disease each year in the United States.
Stanford researches have formulated a robust database called PRECOG (Prediction of Clinical Outcomes from Genomics) that connects cancer genome expression and patient survival/outcomes in a more predictive and extensive collection than any other signature on the market.
Because 98% of the genome does not code for a protein, unraveling how non-coding genetic variants contribute to complex diseases remains a great challenge.